<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Adults with <z:mp ids='MP_0001575'>cyanotic</z:mp> <z:hpo ids='HP_0002564'>congenital heart disease</z:hpo> and elevated hematocrit levels are often phlebotomized because of an assumed risk of cerebral arterial thrombotic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Whether a relation exists between hematocrit level, symptomatic <z:hpo ids='HP_0001901'>erythrocytosis</z:hpo> (hyperviscosity), and <z:hpo ids='HP_0001297'>stroke</z:hpo> remains to be established in this patient population </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Accordingly, 112 <z:mp ids='MP_0001575'>cyanotic</z:mp> patients 19-74 years old (mean, 36 +/- 11.7 years) in the UCLA Adult <z:hpo ids='HP_0002564'>Congenital Heart Disease</z:hpo> Center Registry were selected for study by virtue of continuous observation for 1-12 years (total, 748 patient-years) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with independent risk factors for embolic or vasospastic <z:hpo ids='HP_0001297'>stroke</z:hpo> were excluded </plain></SENT>
<SENT sid="4" pm="."><plain>The study patients were then divided into two groups: 1) compensated <z:hpo ids='HP_0001901'>erythrocytosis</z:hpo> (stable hematocrit levels of 46.0-72.7% [mean, 57.5 +/- 7.2%], iron replete, absent or mild hyperviscosity symptoms), and 2) decompensated <z:hpo ids='HP_0001901'>erythrocytosis</z:hpo> (unstable rising hematocrit levels of 61.5-75.0% [mean, 69.5 +/- 10.6%], <z:e sem="disease" ids="C0240066" disease_type="Disease or Syndrome" abbrv="">iron deficiency</z:e>, marked-to-severe hyperviscosity symptoms) </plain></SENT>
<SENT sid="5" pm="."><plain>No patient with either compensated or decompensated <z:hpo ids='HP_0001901'>erythrocytosis</z:hpo>, irrespective of hematocrit level, iron stores, or the presence, degree, or recurrence of cerebral hyperviscosity symptoms, progressed to clinical evidence of a complete <z:hpo ids='HP_0001297'>stroke</z:hpo> (cerebral <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> with <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Because a risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> caused by cerebral <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> was not demonstrated, because the circulatory effects of phlebotomy are transient, and because of the untoward sequelae of phlebotomy-induced <z:e sem="disease" ids="C0240066" disease_type="Disease or Syndrome" abbrv="">iron deficiency</z:e>, we recommend phlebotomy for the temporary relief of significant, intrusive hyperviscosity symptoms but not for the hematocrit level per se </plain></SENT>
<SENT sid="7" pm="."><plain>According to our data, phlebotomy is not warranted to reduce an assumed risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> because that risk did not materialize </plain></SENT>
</text></document>